Afuco™ Anti-SLAMF7 ADCC Therapeutic Antibody (Elotuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. Elotuzumab is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-743 |
| Pricing | Inquiry |
| Host | Human |
| Target | SLAMF7 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FuncS, IF, Neut, ELISA, FC, IP |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |